Citations

Clear

2960 citation(s) found for "Kim, P".

Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies
Strijdhorst, Anniek , Vos, Winnie G. , Kusters, Pascal , Bosmans, Laura A. , Dzobo, Kim E. , Hanssen, Nordin M J , Kroon, Jeffrey , Lutgens, Esther , Laarhoven, Hanneke W.M. van , Seijkens, Tom T. P. , Es, Nick van

Mayo Clinic

European Heart Journal Supplements | August 1, 2025 | Volume: 27 | Issue: Supplement_6 | Pages: No page available

10.1093/eurheartjsupp/suaf083.005 Get It

Abstract Background Patients with cancer treated with immune checkpoint inhibitors are at increased risk of myocardial infarction and ischemic stroke. The mechanism is incompletely understood but may involve accelerated atherosclerosis due to plaque inflammation. Pre-clinical studies may provide insight in these mechanisms. Aim To assess the effects of modulating co-inhibitory immune checkpoint proteins on atherosclerosis progression in animal models. Methods A systematic review was performed in MEDLINE, Embase, Web of Science, and Scopus up to September 2023. Animal studies were included if the effect of modulation of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and/or lymphocyte-activation gene 3 (LAG-3) on atherosclerotic plaque size was evaluated. Secondary outcomes were plaque composition and systemic inflammation. The ratios of means (RoM) across the studies were pooled in a random effects meta-analysis. Results 1,655 studies were identified of which twelve were included. All studies used an atherosclerotic mouse model (Apoe-/-, Ldlr-/-, or ApoE3*Leiden) and either evaluated pharmacological or genetic modulation of co-inhibitory immune checkpoint proteins. Upon inhibition, atherosclerotic plaque size in the aorta was 49% higher in exposed mice compared to control mice (RoM, 1.49; 95% CI, 1.12-1.82; I2=86%). Plaque composition was predominantly characterized by a greater abundance of CD4+ T cells, CD8+ T cells, and macrophages. Studies stimulating co-inhibitory immune checkpoint proteins corroborated these findings and demonstrated that atherosclerotic plaque size was reduced by 28% in treated mice compared to controls (RoM, 0.72; 95% CI, 0.65-0.80; I2=85%). This reduction was paralleled by a decrease in the number of macrophages and T cells in plaques. Conclusion Immune checkpoint inhibition leads to plaque inflammation and a significant increase in murine atherosclerotic plaque size. These changes may reflect the cause of the increased risk of myocardial infarction and ischemic stroke in patients treated with immune checkpoint inhibitors.
An Integrated Digital Microfluidic Device for the Extraction and Detection of Extracellular Vesicle‐Based Molecules
Lo, Ting‐Wen , Liu, Jing, Zhang, Yuqian , Kim, Yohan , Yao, Janet , Liu, Yuguang , Liu, Yuguang , Liu, Jing, Dong, Haidong , Lucien, Fabrice

Mayo Clinic

Small | July 31, 2025 | Volume: 21 | Issue: 38 | Pages: No page available

10.1002/smll.202504335 | PMID 40739977 Get It

Abstract Extracellular vesicles (EV) are phospholipid‐encapsulated nanoparticles secreted by cells into their surrounding environment. EVs can transfer a variety of biomolecules that mediate intercellular communication and play a key role in physiological and pathological processes. Therefore, EVs are emerging as new biomarkers for diseases, therapeutic targets, and drug delivery vehicles. The isolation and detection of EVs requires time‐consuming and labor‐intensive processes, first to extract EVs from biological and physiological fluids and then to detect EV‐associated molecules with high sensitivity. The methodologies and instruments commonly used for EV analysis are not widely accessible outside of dedicated research laboratories, creating practical barriers for the study of EV‐associated molecules in biology research and clinical applications. To bridge this gap, we developed a proof‐of‐concept digital microfluidic device that can automatedly extract EVs from 20 µL of culture and human plasma samples within 25 min and detect EV‐bound proteins (e.g PD‐L1) on‐chip using an electrochemical sensor. This work serves as a framework for the development of streamlined EV analysis in both research and diagnostics.
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Ahmed, Nausheen , Kambhampati, Swetha , Hamadani, Mehdi , Hu, Zhen‐Huan , Grover, Natalie S. , Shadman, Mazyar , Locke, Frederick L. , Gerson, James N. , Frank, Matthew J. , Budde, Lihua E. , Wang, Michael , Bye, Matthew , Kharfan‐Dabaja, Mohamed A. , Sauter, Craig S. , Logan, Brent R., Nunes, Ana, Dalton, David , Kloos, Ioana , Xu, Hairong, Pasquini, Marcelo C. , Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Grover, Natalie S , Gerson, James , Kim, Soyoung , Kharfan-Dabaja, Mohamed A , Hematti, Peiman , Turtle, Cameron J , Ahmed, Sairah , Moskop, Amy , Nunes, Ana , Dalton, David , Pasquini, Marcelo , Herrera, Alex F , Hamadani, Mehdi , Shadman, Mazyar , Ahmed, Nausheen , Locke, Frederick L , Kim, Soyoung , Hematti, Peiman , Turtle, Cameron J. , Ahmed, Sairah , Moskop, Amy , Lee, Daniel Y.

Mayo Clinic

Blood Advances | July 24, 2025 | Volume: 9 | Issue: 20 | Pages: 5382-5396

10.1182/bloodadvances.2024015014 | PMID 40706035 Get It

Abstract Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell–associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.
Lower Trapezius Tendon Transfer Using Achilles Tendon Allograft Effectively Restores Function After Failed Superior Capsular Reconstruction
Marigi, Erick M. , Baek, Chang Hee , Lim, Chaemoon , Baek, Gyuna , Elhassan, Bassem T. , Marigi, Erick , Kim, Bo Taek , Kim, Jung-Gon

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | July 22, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2025.101222 | PMID 41583800 Get It

Purpose To evaluate the clinical outcomes of lower trapezius tendon (LTT) transfer using an Achilles tendon allograft in patients with failed superior capsular reconstruction (SCR). Methods A retrospective therapeutic review was conducted on patients who underwent LTT transfer using an Achilles tendon allograft after SCR failure between January 2018 and May 2020. The inclusion criteria encompassed both structural and functional failures of SCR in patients with minimal glenohumeral arthritis and a minimum follow‐up of 2 years. Exclusion criteria were insufficient clinical data or loss to follow‐up. Clinical outcomes were assessed preoperatively and at final follow‐up using the visual analog scale (VAS), subjective shoulder value (SSV), Constant score, American Shoulder and Elbow Surgeons (ASES) score, and range of motion (ROM). Results Eighteen patients were included, with a mean follow‐up of 42.5 months (range: 24‐62 months). All outcome measures demonstrated statistically significant improvement: VAS scores improved from 5.9 ± 1.3 to 1.8 ± 1.4; SSV scores improved from 18.0 ± 9.1 to 61.4 ± 18.5; Constant score improved from 33.3 ± 5.3 to 65.5 ± 17.4; and ASES score improved from 38.5 ± 5.2 to 67.1 ± 17.7 (all P < .001). On the basis of the minimal clinically important difference (MCID) using a 0.5 SD distribution‐based method, clinically meaningful improvements were observed in 88.9% of patients for VAS and ASES scores, and 94.4% for Constant and SSV scores. ROM gains included forward elevation (73° to 120°), abduction (57° to 93°), and external rotation (−22° to 40°). At final follow‐up, 77.8% of patients had resumed occupational activities, and 61.1% returned to sports. Four patients (22.2%) required conversion to reverse shoulder arthroplasty. Conclusions LTT transfer using an Achilles tendon allograft following failed SCR yields significant improvements in pain relief, functional outcomes, and ROM. LTT transfer using an Achilles tendon allograft following failed SCR may offer a potential treatment option, particularly in younger, active patients who seek to preserve native shoulder anatomy and function. Level of Evidence Level IV retrospective case series.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines
Carcinomatosis, Expert Panel Management of Peritoneal, Kennedy, Timothy J., Singh, Sareena , Abood, Gerard, Anker, Christopher J. , Akselrod, Dmitriy , Hallemeier, Christopher L. , Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Small, William , Russo, Suzanne , Carcinomatosis, Expert Panel Management of Peritoneal, Christenson, Eric, Jethwa, Krishan R. , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Tchelebi, Leila T.

Mayo Clinic

Cancer Medicine | July 22, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1002/cam4.71043 | PMID 40693544 Get It

ABSTRACT Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin. Aims To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence. Materials and Methods The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology. Results Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary. Discussion Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios. Conclusion A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.
What Is the Appropriate Sample Size in Human Cadaveric Studies? A Quantitative Review of 770 Articles
Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R. , Kikuchi, Keishiro, Kim, Chung Yoh , Ono, Kisho , D'Antoni, Anthony, Komune, Noritaka , Kitagawa, Norio , Kim, Hee‐Jin , Loukas, Marios , Watanabe, Koichi , Tubbs, R. Shane , Iwanaga, Joe , Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R , Kim, Chung Yoh , Ono, Kisho , Komune, Noritaka , Tabira, Yoko , Hur, Mi-Sun , Kim, Hee-Jin , Loukas, Marios , Watanabe, Koichi , Iwanaga, Joe , Cardona, Juan J. , Kikuchi, Keishiro , D’Antoni, Anthony V. , Tabira, Yoko

Mayo Clinic

Clinical Anatomy | July 22, 2025 | Volume: 39 | Issue: 1 | Pages: 14-19

10.1002/ca.70007 | PMID 40692167 Get It

ABSTRACT Determining an appropriate sample size in human cadaveric studies remains a long‐standing and unresolved challenge. Unlike other basic science fields, anatomical research is constrained by factors such as limited human donor availability, cultural considerations, and ethical restrictions. Despite these limitations, researchers are often asked to justify sample sizes, yet no standardized guidelines currently exist. To quantitatively assess sample sizes in recent human cadaveric studies and propose evidence‐based recommendations for future research, a PubMed search was conducted on February 26, 2024, using the term human cadaveric study . The articles published in 2023 and 2024 were screened, yielding 770 eligible studies. Data extracted included the total sample size, number of classified groups, and journal impact factor (IF). Descriptive statistics, linear regression, and correlation analyses were performed. Continuous variables were summarized using medians and interquartile ranges (IQR). The median sample size was 11.5 (IQR: 7–20), and 47.9% of studies used 10 or fewer specimens. The median number of classified groups was 3 (IQR: 2–4). Linear regression showed that studies dividing specimens into 2–6 groups often failed to meet the recommended sample size per group based on regression modeling. No significant correlation was found between sample size and journal IF ( r = −0.062, p = 0.115). Most cadaveric studies rely on small sample sizes due to inherent constraints, yet many still attempt a subgroup analysis without sufficient statistical power. Although flexibility is essential in anatomical research, we recommend a minimum total sample size of 10 for basic studies and at least five samples per group for those involving classification. Cadaveric sample size alone does not predict journal impact, highlighting the importance of methodological rigor over quantity.
Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas
Catalino, Michael P. , Pham, D. T. , Couldwell, William T. , Evans, James J., Callopy, Calen, Pacione, Donato , Suryadevara, Carter M. , Silverstein, Julie , Gardner, Paul A. , Barkhoudarian, Garni , Miranda, Juan Carlos Fernández, Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Zwagerman, Nathan T. , Cheok, Stephanie , Wu, Kyle C., Little, Andrew S. , Karsy, Michael , Couldwell, William T , Chicoine, Michael , Kshettry, Varun R , Van Gompel, Jamie J , Palit, Sandhya R. , Karsy, Michael , Pham, Duy, Rennert, Robert C , Kim, Won Bae , Kim, Albert , Gompel, Jamie J. Van , Prevedello, Daniel M. , Mamelak, Adam N. , Pacult, Mark A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 18, 2025 | Volume: 87 | Issue: 04 | Pages: 406-413

10.1055/a-2646-2339 | PMID 42404182 Get It

Abstract Craniopharyngiomas are rare parasellar tumors, and papillary craniopharyngiomas (PCPs) represent 8 to 20% of cases. Interim analysis of retrospective data collected from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). Fourteen U.S.-based academic skull base centers between 2011 and 2023. Patients with PCPs. Demographic, imaging, surgical, and outcome variables. Ninety-nine patients with PCPs were included. The mean age was 51.8 ± 14.7, and 57.6% were male. Most tumors showed mixed cystic/solid components (67.5%), were transinfundibular (50.0%), and were treated with an endoscopic endonasal approach (74.5%), with 51.1% demonstrating gross total resection (GTR). Pituitary stalk was preserved in 51.9%. Permanent arginine vasopressin deficiency was seen in 67.1% and was associated with pituitary stalk sacrifice (p = 0.003). Cerebrospinal fluid leak was the most common nonendocrine postsurgical, 30-day complication (9.1%), reason for return to the operating room (3.1%), and reason for 90-day readmission (8.1%). Most patients (63.9%) received no adjuvant therapy; GTR was associated with decreased radiotherapy use (p = 0.0001). BRAFV600E mutation was detected in 64/69 tumors tested, although only one patient was treated with a BRAF inhibitor. A mean follow-up of 12.3 ± 14.6 months was seen for the group. RAPID consortium enabled the largest real-world clinical information dataset for PCPs. Early findings support that GTR and stalk preservation are important to outcomes. Iterative analysis and discussion of data led to the generation of a framework for future studies to fully leverage the capabilities of multicenter registries.
The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
Dratch, Laynie , Jenny, Kim, Salmon, Kristiana , Crook, Ashley , Uhlmann, Wendy R. , Fong, Jamie , Klee, Victoria , MacLeod, Rhona, Chaouch, Amina , Lucente, Diane , Mantia, Sarah K., Pagano, Jennifer, Mu, Weiyi , Fong, Jamie , Goldman, Jill S , Chaouch, Amina , Goldman, Jill

Mayo Clinic

Neurology | July 18, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213814 | PMID 40680239 Get It

Barriers and facilitators of cardiovascular disease prevention services for women with prior gestational diabetes or hypertensive disorders of pregnancy: a scoping review
Quansah, Dan Yedu , Visintini, Sarah , Kim, Helena, Harris, Laura, Dai, Nini , O’Neill, Carley , Savard, Karine, Coutinho, Thais , Mullen, Kerri‐Anne, Coutinho, Thais D. , Ahmed, S. Faisal , Dai, Nichole, Savard, Karine, Mir, Hassan R.

Mayo Clinic

European Journal of Preventive Cardiology | July 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf435 | PMID 40694664 Get It

Abstract Aims Although cardiovascular disease (CVD) screening and preventive care in the early postpartum are recommended for women with prior gestational diabetes (GDM) and hypertensive disorders of pregnancy (HDP), certain barriers limit access to such services. We conducted a scoping review to summarize evidence on the barriers and facilitators of CVD prevention services among women with prior GDM or HDP. Methods and results A comprehensive search strategy was used to search articles published in three databases (Ovid Medline, CINAHL, Embase). Studies published in English or French that investigated and reported barriers or facilitators to postpartum CVD screening and preventive care among women with previous GDM and HDP were included. Out of 18 565 studies we screened, 29 studies (12 qualitative, 17 quantitative) were included. Main individual level barriers including lack of knowledge, health, and emotional factors were identified. Competing priorities, lack of family/friend support, and mistrust of healthcare providers were the most reported interpersonal level barriers, while gaps in communication were the most significant organizational barrier, and gaps in insurance coverage was the most reported system barrier. Individual level facilitators included a personal desire for better health and availability of postpartum programmes, and the most reported interpersonal facilitator was women's commitment to modelling a healthy lifestyle for their children. Organizational level facilitators were access to primary care providers and follow-up visit reminders, and programme availability in native languages. Conclusion Women with prior GDM or HDP face significant barriers to accessing postpartum CVD prevention services. These barriers ranged from individual-level knowledge gaps to system-level healthcare disparities.